62 related articles for article (PubMed ID: 21387300)
1. Antitumor effect of sunitinib against skeletal metastatic renal cell carcinoma through inhibition of osteoclast function.
Maita S; Yuasa T; Tsuchiya N; Mitobe Y; Narita S; Horikawa Y; Hatake K; Fukui I; Kimura S; Maekawa T; Habuchi T
Int J Cancer; 2012 Feb; 130(3):677-84. PubMed ID: 21387300
[TBL] [Abstract][Full Text] [Related]
2. Adrenomedullin blockade suppresses sunitinib-resistant renal cell carcinoma growth by targeting the ERK/MAPK pathway.
Gao Y; Li J; Qiao N; Meng Q; Zhang M; Wang X; Jia J; Yang S; Qu C; Li W; Wang D
Oncotarget; 2016 Sep; 7(39):63374-63387. PubMed ID: 27556517
[TBL] [Abstract][Full Text] [Related]
3. EMMPRIN promotes angiogenesis, proliferation, invasion and resistance to sunitinib in renal cell carcinoma, and its level predicts patient outcome.
Sato M; Nakai Y; Nakata W; Yoshida T; Hatano K; Kawashima A; Fujita K; Uemura M; Takayama H; Nonomura N
PLoS One; 2013; 8(9):e74313. PubMed ID: 24073208
[TBL] [Abstract][Full Text] [Related]
4. Tumor Xenografts of Human Clear Cell Renal Cell Carcinoma But Not Corresponding Cell Lines Recapitulate Clinical Response to Sunitinib: Feasibility of Using Biopsy Samples.
Dong Y; Manley BJ; Becerra MF; Redzematovic A; Casuscelli J; Tennenbaum DM; Reznik E; Han S; Benfante N; Chen YB; Arcila ME; Aras O; Voss MH; Feldman DR; Motzer RJ; Fabbri N; Healey JH; Boland PJ; Chawla M; Durack JC; Lee CH; Coleman JA; Russo P; Hakimi AA; Cheng EH; Hsieh JJ
Eur Urol Focus; 2017 Dec; 3(6):590-598. PubMed ID: 28753786
[TBL] [Abstract][Full Text] [Related]
5. Epigenome screening highlights that JMJD6 confers an epigenetic vulnerability and mediates sunitinib sensitivity in renal cell carcinoma.
Zhang C; Lu X; Huang J; He H; Chen L; Liu Y; Wang H; Xu Y; Xing S; Ruan X; Yang X; Chen L; Xu D
Clin Transl Med; 2021 Feb; 11(2):e328. PubMed ID: 33634984
[TBL] [Abstract][Full Text] [Related]
6. Effect of Acridine Orange and Zoledronic Acid on Bone Metastasis in Renal Cell Carcinoma.
Oya K; Tsuchie H; Nagasawa H; Hongo M; Kasukawa Y; Kudo D; Shoji R; Kasama F; Kawaragi T; Watanabe M; Tominaga K; Miyakoshi N
Anticancer Res; 2024 Jun; 44(6):2487-2495. PubMed ID: 38821618
[TBL] [Abstract][Full Text] [Related]
7. A multifunctional antibody fusion protein 57103 targeting CD24, IL-4R, and α
Xu X; Li J; Setrerrahmane S; Zhang J; Shi S; Hu Y; Lin D; Xu H
Biomed Pharmacother; 2024 Jun; 175():116714. PubMed ID: 38761419
[TBL] [Abstract][Full Text] [Related]
8. Potential therapeutic target secretogranin II might cooperate with hypoxia-inducible factor 1α in sunitinib-resistant renal cell carcinoma.
Fukumoto W; Yoshino H; Horike SI; Kawakami I; Tamai M; Arima J; Kawahara I; Mitsuke A; Sakaguchi T; Inoguchi S; Meguro-Horike M; Tatarano S; Enokida H
Cancer Sci; 2023 Oct; 114(10):3946-3956. PubMed ID: 37545017
[TBL] [Abstract][Full Text] [Related]
9. Venetoclax Synergizes Sunitinib in Renal Cell Carcincoma through Inhibition of Bcl-2.
Tang Y; Song T; Gao L; Mao F
Anticancer Agents Med Chem; 2023; 23(18):2027-2034. PubMed ID: 37581518
[TBL] [Abstract][Full Text] [Related]
10. Elucidation and Regulation of Tyrosine Kinase Inhibitor Resistance in Renal Cell Carcinoma Cells from the Perspective of Glutamine Metabolism.
Morozumi K; Kawasaki Y; Sato T; Maekawa M; Takasaki S; Shimada S; Sakai T; Yamashita S; Mano N; Ito A
Metabolites; 2024 Mar; 14(3):. PubMed ID: 38535330
[TBL] [Abstract][Full Text] [Related]
11. Nilotinib in combination with sunitinib renders MCL-1 for degradation and activates autophagy that overcomes sunitinib resistance in renal cell carcinoma.
Liu T; Yue X; Chen X; Yan R; Wu C; Li Y; Bu X; Han H; Liu RY
Cell Oncol (Dordr); 2024 Feb; ():. PubMed ID: 38393513
[TBL] [Abstract][Full Text] [Related]
12. Sunitinib does not impair natural killer cell function in patients with renal cell carcinoma.
Moeckel J; Staiger N; Mackensen A; Meidenbauer N; Ullrich E
Oncol Lett; 2017 Jul; 14(1):1089-1096. PubMed ID: 28693278
[TBL] [Abstract][Full Text] [Related]
13. Tumor Supplying Artery Injection of Liposome@Sunitinib Could Effectively Inhibit the Progression of Kidney Tumor.
Fu Q; Li G; Wang L; Yin C; Yi B; Huang Y; Su Q; Zhang Z; Zhu J
ACS Appl Mater Interfaces; 2024 Apr; ():. PubMed ID: 38624141
[TBL] [Abstract][Full Text] [Related]
14. Amiloride reduces fructosamine-3-kinase expression to restore sunitinib sensitivity in renal cell carcinoma.
Bai Y; You Y; Chen D; Chen Y; Yin Z; Liao S; You B; Lu D; Sun Y; Wu L; Wu Y
iScience; 2024 Jun; 27(6):109997. PubMed ID: 38868177
[TBL] [Abstract][Full Text] [Related]
15. Metastatic Kidney Cancer: Does the Location of the Metastases Matter? Moving towards Personalized Therapy for Metastatic Renal Cell Carcinoma.
Baston C; Parosanu AI; Stanciu IM; Nitipir C
Biomedicines; 2024 May; 12(5):. PubMed ID: 38791072
[TBL] [Abstract][Full Text] [Related]
16. Development of a New Focal Mouse Model of Bone Metastasis in Renal Cell Carcinoma.
Oya K; Tsuchie H; Nagasawa H; Hongo M; Kasukawa Y; Kudo D; Shoji R; Kasama F; Kawaragi T; Watanabe M; Tominaga K; Miyakoshi N
In Vivo; 2024; 38(3):1074-1078. PubMed ID: 38688604
[TBL] [Abstract][Full Text] [Related]
17. Bone Metabolism Effects of Medical Therapy in Advanced Renal Cell Carcinoma.
Paragliola RM; Torino F; Barnabei A; Iannantuono GM; Corsello A; Locantore P; Corsello SM
Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672478
[TBL] [Abstract][Full Text] [Related]
18. Choosing The Right Animal Model for Renal Cancer Research.
Sobczuk P; Brodziak A; Khan MI; Chhabra S; Fiedorowicz M; Wełniak-Kamińska M; Synoradzki K; Bartnik E; Cudnoch-Jędrzejewska A; Czarnecka AM
Transl Oncol; 2020 Mar; 13(3):100745. PubMed ID: 32092671
[TBL] [Abstract][Full Text] [Related]
19. An interdisciplinary consensus on the management of bone metastases from renal cell carcinoma.
Grünwald V; Eberhardt B; Bex A; Flörcken A; Gauler T; Derlin T; Panzica M; Dürr HR; Grötz KA; Giles RH; von Falck C; Graser A; Muacevic A; Staehler M
Nat Rev Urol; 2018 Aug; 15(8):511-521. PubMed ID: 29904105
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
